TY  - JOUR
AU  - Hammes, Jochen
AU  - Drzezga, Alexander
AU  - van Eimeren, Thilo
TI  - The Role of Tau Imaging in Parkinsonian Disorders
JO  - Current neurology and neuroscience reports
VL  - 18
IS  - 12
SN  - 1534-6293
CY  - Philadelphia, Pa.
PB  - Current Science Inc.
M1  - FZJ-2018-05725
SP  - 86
PY  - 2018
AB  - Purpose of ReviewDifferential diagnosis of atypical Parkinson syndromes (APS) is difficult as clinical presentations may vary and as there is a strong overlap between disease entities. Aggregations of misfolded and hyperphosphorylated tau proteins are the common denominator of many of these diseases.Recent FindingsSeveral tau targeting positron emission tomography (PET) tracers have been evaluated as possible biomarkers in APS in the recent years. For Parkinson’s disease, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal degeneration, promising results have been reported with regard to the ability to detect the presence of disease and to discriminate patients from controls. However, the discussion about the specificity of the first-generation radiotracers and their value in the clinical context is ongoing.SummaryA combined interpretation of signal strength and distribution pattern in PET scans with first- and second-generation tracers may be helpful in clinical diagnosis and follow-up of patients with APS
LB  - PUB:(DE-HGF)16
C6  - pmid:30293094
UR  - <Go to ISI:>//WOS:000446537500003
DO  - DOI:10.1007/s11910-018-0898-3
UR  - https://juser.fz-juelich.de/record/856060
ER  -